$2.76
-0.14 (-4.83%)
Open$2.87
Previous Close$2.90
Day High$2.88
Day Low$2.60
52W High$5.38
52W Low$2.23
Volume—
Avg Volume168.5K
Market Cap117.44M
P/E Ratio—
EPS$-3.50
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+660.9% upside
Current
$2.76
$2.76
Target
$21.00
$21.00
$13.91
$21.00 avg
$28.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.03M | 5.08M | 4.69M |
| Net Income | 1.10M | 914.1K | 814.2K |
| Profit Margin | 21.9% | 18.0% | 17.4% |
| EBITDA | 1.45M | 1.42M | 1.49M |
| Free Cash Flow | 1.19M | 761.6K | 738.1K |
| Rev Growth | -9.3% | +7.5% | +3.9% |
| Debt/Equity | 1.05 | 1.23 | 1.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |